Rafael Holdings names new CFO
15 September 2021 -

Rafael Holdings, Inc, (NYSE: RFL), a pharmaceutical holding company, announced on Tuesday that it has named Patrick Fabbio as its new chief financial officer.

Fabbio has over 25 years of financial, operational and transactional leadership experience in the pharmaceutical sector. He has served as CFO of WindMIL Therapeutics Inc, CFO of Progenics Pharmaceuticals, Inc, electroCore Medical, LLC; Vice President of Finance at NPS Pharmaceuticals, Inc.; VP of Finance, Innovation and Growth at Catalent Pharma Solutions Inc.; and CFO at Ikano Therapeutics, and has held financial positions at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. He is also a board member of BeyondSpring Therapeutics, Inc.

Ameet Mallik, Chief Executive Officer of Rafael Holdings, Inc, said, 'We are pleased to have attracted someone with Pat's extensive financial experience as we approach the completion and data readout of the Phase 3 registrational clinical trial for Rafael Pharmaceuticals' lead investigational agent, CPI-613(R), for the treatment of metastatic pancreatic cancer expected in the fourth quarter of this year. Pat joins our growing executive management team as we work to build a high growth, fully integrated cancer metabolism therapeutics company focused on improving and extending the lives of cancer patients.'